FDA Approves Targeted Therapy Combo for Thyroid Cancer

On May 4, the U.S. Food and Drug Administration (FDA) approved a combination of molecularly targeted therapeutics for the treatment of a certain type of thyroid cancer. Specifically, the FDA approved the use of dabrafenib (Tafinlar) in combination with trametinib (Mekinist) for treating patients who have anaplastic thyroid cancer that cannot be removed by surgery or that has metastasized, and that tests positive for a BRAF V600E gene mutation.

Read More

AACR Annual Meeting 2018: Novel Immunotherapy Combinations to Combat Resistance to Checkpoint Inhibition

An exciting area in drug development, immunotherapy is being increasingly utilized by patients with different cancer types. These treatments work by stimulating the patient’s immune system to effectively target and …

Read More